Johnson & Johnson pays $785 million upfront for an option to buy Flagship-backed Sail Biomedicines, whose nanoparticle-and-RNA platform aims to make CAR-T inside the body.
The all-stock reverse merger, paired with a $278 million private placement, creates a Nasdaq-listed company built around CLD-423 for inflammatory bowel disease.
LTG-001, an oral Nav1.8 blocker, eased post-surgical pain and cut opioid rescue use in a 343-patient trial published in the New England Journal of Medicine.
The oral immunology drug ritlecitinib hit its co-primary endpoints in the TRANQUILLO studies, setting up filings for nonsegmental vitiligo, a condition with no approved oral therapy.
Vertex pays $28 million upfront and will fund all R&D for multispecific antibodies AbCellera discovers, pushing T-cell engagers beyond cancer into autoimmunity.
The Tokyo AI firm and Julien Orts’s NMR lab will combine machine learning with atomic-resolution spectroscopy to target intrinsically disordered proteins in cancer.
In the 106-patient HOPE-3 trial, boys and young men on deramiocel lost arm and elbow function markedly slower than those on placebo, ahead of an August FDA decision.
University of Illinois researchers rewrote how the huntingtin gene is read, cutting toxic protein fragments and brain damage in mice — an early, preclinical step.
The AI-first primary-care startup adds Summer Health’s text-based pediatric service and a 100,000-message dataset to cover care ‘from birth through adulthood.’
The all-stock deal, paired with a $200 million raise, hands Processa a once-daily, brain-penetrating BTK inhibitor targeting food allergy, chronic urticaria and multiple sclerosis.
Strong specialty-medicine sales lifted GSK's second quarter as the drugmaker doubles down on oncology — and braces for looming HIV patent losses.
As GLP-1 drugs go from niche to blockbuster, the industry is scrambling for the specialized manufacturing skills needed to keep up with demand.